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Abstract
We previously found that myocardial ischemia/reperfusion (I/R) initiates expression of tumor
necrosis factor-α (TNF) leading to coronary endothelial dysfunction. However, it is not clear whether
there is a direct relationship between levels of TNF expression and endothelial dysfunction in
reperfusion injury. We studied levels of TNF expression by using different transgenic animals
expressing varying amounts of TNF in I/R. We crossed TNF overexpression (TNF++/++) with TNF
knockout (TNF−/−) mice; thus we have a heterozygote population of mice with the expression of
TNF “in between” the TNF−/− and TNF++/++ mice. Mouse hearts were subjected to 30 min of global
ischemia followed by 90 min of reperfusion and their vasoactivity before and after I/R was examined
in wild type (WT), TNF−/−, TNF++/++ and TNF heterozygote (TNF−/++, cross between TNF−/− and
TNF++/++) mice. In heterozygote TNF−/++ mice with intermediate cardiac-specific expression of
TNF, acetylcholine-induced or flow-induced endothelial-dependent vasodilation following I/R was
between TNF++/++ and TNF−/− following I/R. Neutralizing antibodies to TNF administered
immediately before the onset of reperfusion-preserved endothelial-dependent dilation following I/R
in WT, TNF−/++ and TNF++/++ mice. In WT, TNF−/++ and TNF++/++ mice, I/R-induced endothelial
dysfunction was progressively lessened by administration of free-radical scavenger TEMPOL
immediately before initiating reperfusion. During I/R, production of superoxide (O2·−) was greatest
in TNF++/++ mice as compared to WT, TNF−/++ and TNF−/− mice. Following I/R, arginase mRNA
expression was elevated in the WT, substantially elevated in the TNF−/++ and TNF++/++ mice and
not affected in the TNF−/− mice. These results suggest that the level of TNF expression determines
arginase expression in endothelial cells during myocardial I/R, which is one of the mechanisms by
which TNF compromises coronary endothelial function in reperfusion injury.
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Introduction
Cytokines [e.g., tumor necrosis factor-α (TNF), interlukin-1 (IL-1) and IL-2] are postulated as
mediators of ischemia/reperfusion (I/R) [5,21,34,42,45]. These factors are of direct relevance
to endothelial dysfunction, since cytokines exert a prominent anti-endothelium-derived
relaxing factor effect in blood vessels [2,21]. Ischemia alone induces TNF gene expression and
peptide synthesis in the myocardium, that is, associated with nuclear factor-κB (NF-κB)
activation [2,21,41,44]. Superoxide (O2·−) may be dismutated (spontaneously or
enzymatically) to hydrogen peroxide (H2O2), which is another oxidant, and, therefore, another
possible mediator of oxidant injury. The reaction of nitric oxide (NO) and O2·− produces the
formation of peroxynitrite (ONOO−) which is a potent oxidant [28,41,42,44,45], and a previous
study has shown that TNF inhibits NO-mediated endothelium-dependent vasorelaxation in
small coronary arteries via sphingomyelinase activation and consequent O2·− production in
endothelial cells (ECs) [4,30,47]. However, it has not been elucidated whether there is a direct
relationship between levels of TNF expression and endothelial dysfunction in reperfusion
injury.
Many in vivo and in vitro studies show endothelial-dependent dilation to agonists, e.g.,
acetylcholine (ACh), is impaired in I/R injury. We have reported that TNF inhibits
endothelium-dependent NO-mediated dilation of coronary arterioles via production of O2·− in
porcine coronary arterioles [44]. We also found that myocardial I/R initiates expression of
TNF, which induces activation of xanthine oxidase and production of O2·−, leading to coronary
endothelial dysfunction [44]. ACh-induced NO-dependent dilation was found to be impaired
following I/R in WT mice and this deficit was ameliorated by neutralizing antibodies against
TNF (Fig. 1) [46]. We previously demonstrated that TNF upregulates expression of arginase
in ECs, which leads to O2·− production, then induces endothelial dysfunction in I/R injury
[9]. We also observed greater endothelial injury in TNF++/++ animals as compared to WT
animals after I/R and less damage after I/R in TNF−/− animals as compared to WT mice [9].
Thus, we hypothesized that endothelial function following I/R in TNF heterozygote
(TNF−/++) mice would be intermediate between that of TNF overexpression (TNF++/++) and
TNF knockout (TNF−/−) mice. The purpose of our study was to evaluate whether a direct
relationship between levels of TNF expression and endothelial dysfunction occurred in
reperfusion injury by determining NO-mediated vasodilation to ACh in isolated and
pressurized coronary arterioles and O2·− production and expression of arginase in wild type
(WT), TNF−/−, TNF−/++ and TNF++/++ mice (Fig. 1).
Methods
Murine I/R model
The procedures followed were in accordance with approved guidelines set by the Laboratory
Animal Care Committee at University of Missouri–Columbia. This study utilized 12- to 15-
week-old, 25- to 35-g mice of either sex. We used three different strains of WT mice to match
the backgrounds of the knockout (TNF−/−), transgenic (TNF++/++) and heterozygote
(TNF−/++) mice. For the TNF−/− mice (Parental strain B6, 129S-Tnftm1Gkl, stock number is
003008. Jackson Laboratory, Bar Harbor, ME), the WT1 is strain B6, 129SF2/J (stock number
is 101045, Jackson Laboratory, Bar Harbor, ME). Mice homozygous (TNF++/++) for the
TNFtmIGkl-targeted mutation are viable, fertile and show no apparent phenotypic
abnormalities. TNF++/++ mice completely lack splenic primary B-cell follicles and cannot form
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organized follicular dendritic cell networks and germinal centers. For the transgenic
overexpression mice TNF++/++ [46], the parental strain for this transgenic line is the FVBN,
and WT2 controls for this group consist of the FVBN line. The transgenic mouse heart
demonstrated a mild, diffuse, lymphohistiocytic interstitial inflammatory infiltrate.
Cardiomyocyte necrosis and apoptosis were present, but not abundant. Magnetic resonance
imaging showed that the transgenic mouse heart was significantly dilated with reduced ejection
fraction. Heterozygote TNF−/++ mice are the crosses between TNF−/− and TNF++/++ mice with
intermediate cardiac-specific expression of TNF. The control mice (WT3) are the crosses
between WT1 and WT2, which have the same background with TNF−/++ mice. The surgical
protocol was performed similar to methods described previously [9,10,46] with minor
modification. After 30 min of the left anterior descending (LAD) coronary artery occlusion
and 90 min of reperfusion, the heart was harvested and used for functional study or other assays.
A sham group was subjected to the same surgical interventions without performing occlusions.
We defined WT1, 2 and 3 as WT in this study because the results from WT1, 2 and 3 were
identical.
Treatment with TNF and TNF neutralization
We administered TNF (5 μg/kg, i.p., R&D Systems) to WT mice for 3 days to determine
whether such a lower level of TNF can inhibit coronary arterial dilations mediated by NO
[27]. The neutralizing antibody to TNF (anti-TNF) used in these studies was IgG goat
polyclonal antibody prepared to be essentially lipopolysaccharide free. At 12 weeks of age, all
mice were administered with the neutralizing antibodies to TNF (anti-TNF IgG. i.p., 0.1 mg/
mouse containing 16 mg protein/mL, immediately prior to the onset of reperfusion). This
concentration was based on previous studies and sufficient to neutralize endogenous TNF [9,
10,46].
Functional assessment of isolated coronary arterioles
The techniques for identification and isolation of coronary microvessels were described in
detail previously [9,10,46]. After I/R, the heart was excised and immediately placed in cold
(4°C) saline solution. Each coronary arteriole (50–100 μm in internal diameter) was carefully
isolated and then used in the functional and molecular studies described below. To determine
the response of coronary arterioles to ACh, vessels were cannulated with glass micropipettes
and pressurized to 60 cm H2O intraluminal pressure. The cannulated vessel was bathed in
physiological salt solution (PSS; mmol/L: NaCl 145.0, KCl 4.7, CaCl2 2.0, MgSO4 1.17,
NaH2PO4 1.2, glucose 5.0, pyruvate 2.0, EDTA 0.02 and Mops 3.0) containing bovine serum
albumin (1%; Amersham) at 37°C. For functional studies, vessels were cannulated with glass
micropipettes and pressurized to 60 cm H2O luminal pressure without flow. After developing
a stable basal tone (i.e., spontaneous constriction to 60–70% of maximal diameter), the
experimental interventions were performed. The concentration–diameter relationships for ACh
(0.1 nmol/L to 10 μmol/L) and sodium nitroprusside (SNP, 1 nmol/L to 1 μmol/L) were then
established. We also tested the dose–response curve to flow-dependent dilation [range of ΔP
(that is linearly related to flow) from 4 to 60 cm H2O], a response that is endothelial dependent,
but agonist independent.
To determine whether different levels of TNF were playing a role in endothelial injury
following I/R, endothelial dependent and independent dilation were assessed in coronary
arterioles from anti-TNF IgG-treated mice. ACh or flow was used as an activator of
endothelium-dependent NO-mediated vasodilation [9,10,46]. To mimic the cross of WT with
the TNF null (TNF−/−) animals, we determined whether endothelial function in the presence
of a lower level of TNF (5 μg/kg, i.p., 3 days, R&D Systems) in WT I/R mice treated with anti-
TNF is in between of WT I/R and WT I/R mice treated with anti-TNF. To determine the role
of TNF and O2·− anions in murine I/R, vasodilatory functions were examined in the presence
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of a membrane-permeable O2·− dismutase mimetic, TEMPOL (1 mmol/L, 60-min incubation).
All drugs were administered extraluminally in these functional studies.
Plasma concentration of TNF
Tumor necrosis factor was measured using a commercial kit BIO-Plex cytokine assay (BIO-
Plex Mouse 3-Plex Assay, Bio-Rad Laboratories, CA, USA). TNF concentrations were
automatically calculated by BIO-Plex Manager software using a standard curve derived from
a recombinant cytokine standard. Values were expressed as picogram per milliliter [46].
Measurement of O2·− by electron paramagnetic resonance spectroscopy
A 10% vessel homogenate was prepared in a 50 mmol/L phosphate buffer containing 0.01
mmol/L EDTA. The homogenate was then subjected to low-speed centrifugation (1,000g) for
10 min to remove unbroken cells and debris. The supernatants containing 2 mmol/L CP-H (1-
hydrox-3 carboxypyrrolidine) were incubated for 30 min at 37°C and frozen quickly in liquid
nitrogen. Electron paramagnetic resonance (EPR) spectroscopy was performed at room
temperature using a Bruker EMX spectrometer and 1-mm diameter capillaries. The EPR
spectrum settings were as follows: modulation amplitude 1.0 gauss, scan time 83 s, time
constant 163 ms and microwave power 40 mW, field sweep 60 gauss, microwave frequency
9.78 GHz, receiver gain 5 × 103, center field 3,485 gauss. Superoxide quantitation from the
EPR spectra was determined by double integration of the peaks, with reference to a standard
curve generated from horseradish peroxidase generation of the anion from standard solutions
of H2O2, using p-acetamidophenol as the cosubstrate, and then normalized by protein
concentration.
Arginase expression by Western blotting and real-time PCR
For Western blot analysis, isolated coronary arterioles (3–4 vessels per sample) from WT,
TNF−/−, TNF−/++, TNF++/++ mice before and after I/R were homogenized and sonicated in
lysis buffer. Protein concentrations were assessed with the use of the BCA kit, and equal
amounts of protein (40 μg) were separated by SDS–PAGE and transferred to nitrocellulose
membranes (Bio-Rad). The protein expression of arginase I was tested with the use of rabbit
arginase I polyclonal IgG primary antibody (Santa-Cruz Biotechnology). Horseradish
peroxidase-conjugated goat anti-rabbit IgG was used as the secondary antibody (Abcam).
Signals were visualized by enhanced chemiluminescence (Santa-Cruz) and quantified by
Quantity One (Bio-Rad Versadoc imaging system).
Total RNA was extracted from left ventricular coronary arterioles using Trizol reagent (Life
Technologies Inc.), and was processed directly to cDNA synthesis using the SuperScript™ III
Reverse Transcriptase (Life Technologies Inc.) [9,10,46]. The 2−ΔΔCT method (ΔΔCT =
CT-TNFα-CT-GAPDH) was used to analyze the change of TNF gene expression [39]. The mean
threshold cycle (CT) values for both the target (arginase) and internal control (GAPDH) genes
were determined. Data are presented as fold change of transcripts for the arginase gene in I/R
mice normalized to GAPDH, as compared to sham mice (defined as 1.0-fold).
Assay of NOS activity and arginase activity in I/R
Nitric oxidase synthase (NOS) detection kit (Cell Technology, Inc.) was used for testing the
NOS activity. Coronary arterioles (5–7 vessels/sample, 100-μm inner diameter) in WT,
TNF−/−, TNF−/++ and TNF++/++ mice in sham and I/R were freshly isolated. NOS activity can
be measured via fluorescence plate reader at excitation 488 nm and emission at 515 nm. Data
are presented as fold change when compared with sham-control mice (defined as 1.0-fold).
The urea concentration (for arginase activity assay) was determined spectrophotometrically by
the absorbance at 550 nm measured with a microplate reader (Bio-Tek Instruments). The
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amount of urea produced, after normalization with protein, was used as an index for arginase
activity.
Chemicals—All drugs were obtained from Sigma, except as specifically stated. ACh, SNP
and TEMPOL were dissolved in PSS for functional studies and in phosphate-buffered saline
for fluorescence detection. Vehicle control studies indicated that these final concentrations of
solvent had no effect on the arteriolar function.
Data analysis—At the end of each experiment, the vessel was relaxed with 100 μmol/L SNP
to obtain its maximal diameter at 60 cm H2O intraluminal pressure [9,10,30]. All diameter
changes in response to agonists were normalized to the vasodilation in response to 100 μmol/
L SNP and expressed as a percentage of maximal dilation. All data are presented as mean ±
SEM. Statistical comparisons of vasomotor responses under various treatments were
performed with two-way ANOVA and intergroup differences were tested with Bonferonni
inequality. Significance was accepted at P < 0.05.
Results
Plasma concentration of TNF
Table 1 shows the plasma concentration of TNF in circulating levels in sham and I/R injury in
WT, TNF−/−, TNF−/++ and TNF++/++ mice.
Roles of dose dependency of TNF in I/R-induced vascular dysfunction
The dilation to ACh, or flow was the best in the TNF−/−, worst in the TNF++/++, and
intermediate in the WT and TNF−/++ mice following I/R versus sham controls (Fig. 2).
Administration of neutralizing antibodies to TNF prior to the onset of reperfusion lessened
endothelial dysfunction in reperfusion injury in WT, TNF−/++ and TNF++/++ mice, but not
affect responses in TNF−/− mice. Importantly, neutralizing antibodies to TNF restored flow-
induced dilation (FID) to near the sham-control levels in I/R (Fig. 3).
Figure 3e shows a dose–response curve for SNP in WT control mice before and after I/R. There
are no significant differences in endothelium-independent vasodilator SNP-induced
vasodilation before and after I/R. These results demonstrate an unchanged response to SNP
among the different groups analyzed and assure that effects are related to the endothelium
rather than to vascular smooth muscle cell alterations. Figure 3f shows that endothelial function
is restored in I/R at WT mice treated with anti-TNF (mimicked the cross of WT with the TNF
null animals), endothelial function is impaired with a lower level of TNF in WT mice, and
endothelial function is in between of these two groups with a lower level of TNF in WT mice
treated with anti-TNF. These results indicated that I/R contributes endothelial dysfunction via
increasing TNF level in coronary arterioles.
Roles of O2·− in I/R-induced vascular dysfunction
We incubated TEMPOL with isolated microvessels for 60 min (1 mmol/L) then examined
vasodilation induced by ACh. Administration of an O2·− scavenger TEMPOL (Fig. 4)
maintained vasodilation to ACh in I/R, but did not affect ACh-induced vasodilation in sham
groups. TEMPOL partially restored ACh-induced vasodilation after I/R injury in WT,
TNF−/++ and TNF++/++ mice, but did not affect that in TNF−/− mice.
I/R-induced O2·− production in murine coronary arterioles
Figure 5 shows the results from EPR spectroscopy to quantify the production of O2·−. O2·−
production increased after I/R as compared to the sham group (P < 0.05), and importantly,
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administration of anti-TNF (Fig. 5a), or free-radical scavenger TEMPOL (Fig. 5b) reduced the
expression of O2·− to the level observed in the sham group. O2·− production was enhanced in
the TNF++/++ group before and after I/R when compared with WT groups. Production of
O2·− is less in the TNF−/− mice following I/R versus I/R in WT mice. The production of O2·−
was intermediate in TNF−/++ I/R mice occurring between that of TNF++/++ and TNF−/− mice
following I/R.
Effect of TNF on arginase I expression in coronary arterioles during I/R
The protein expression of arginase I was lower in TNF−/− mice, higher in TNF++/++ mice, and
in between of TNF−/− and TNF++/++ mice in TNF−/++ mice than that in WT mice (Fig. 6a, b).
The mRNA expression of arginase I was lower in TNF−/− mice and higher in TNF++/++ mice
than that in WT mice (Fig. 6c), which suggested that arginase titer is inversely linked to TNF
titer. Arginase expression was significantly increased in WT I/R mice, but was not changed in
TNF−/− mice following I/R. I/R increased arginase expression in TNF−/++ mice, but did not
increase arginase expression in TNF++/++ mice, perhaps because arginase expression mediated
by TNF was already maximal or saturated in the TNF++/++ mice. We previously reported that
anti-TNF decreased arginase I expression in WT-I/R versus WT-sham mice [9, 10, 46]. These
results suggested that a “dose dependency” of TNF plays an important role in upregulating
arginase progressively in I/R, which may then cause the impairment of NO-mediated
vasodilation in I/R.
NOS and arginase activity in I/R
Activity of NOS and arginase was assayed in the coronary arteriolar lysate to further elucidate
the role of TNF-α in the upregulation of arginase in I/R (Fig. 7). We found that reduced eNOS
activity (Fig. 7a) in WT, TNF−/−, TNF−/++, TNF++/++ versus WT-sham mice and arginase
activity (Fig. 7b) is increased in I/R in WT-I/R, TNF−/++, TNF++/++ versus WT-sham and
TNF−/− mice.
Discussion
Our major finding is that increasing levels of TNF expression result in dose-dependent
increases in arginase expression in ECs during myocardial I/R; this is one of the mechanisms
by which TNF compromises coronary endothelial function (Fig. 1). Our results suggest a direct
relationship between levels of TNF expression and endothelial dysfunction in reperfusion
injury. We believe that our findings further understanding of the mechanism(s) underlying
endothelial dysfunction following myocardial I/R injury.
Role of levels of TNF expression in I/R-induced endothelium-dependent dilation in murine
coronary arterioles
We have established the critical role of TNF in I/R impaired endothelial function in coronary
arterioles, and suggest that TNF plays an important role in endothelial dysfunction during I/R
injury. The mechanisms of I/R injury are multifactorial and incompletely understood. Many
agents have been directed at preserving cardiac myocytes, but few have targeted the
endothelium. Perhaps, this is the very reason that the therapies failed because without adequate
flow during reperfusion, functional recovery is likely to be poor. Our study was designed to
mimic a clinically relevant paradigm in which an antibody designed to neutralize TNF could
be delivered at the time of a recanalization procedure or restoration of flow following a coronary
bypass. Reperfusion is associated with the rapid expression of genes for antioxidant enzymes,
which may enhance reactive oxygen intermediate scavenging [6]. Herskowitz et al. [15]
reported that the induction of cytokine mRNA was observed at 15 min of LAD occlusion, with
levels returning to baseline by 3 h in a model of myocardial I/R. Several studies have reported
reversible myocardial dysfunction in normal animals in response to systemic administration
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of TNF [6,24,35]. TNF inhibits NO-mediated endothelium-dependent vasorelaxation in small
coronary arteries via sphingomyelinase activation and consequent O2·− production in ECs
[47]. Gilmont et al. [12] have shown a direct effect of TNF on EC, whereby the cells are
rendered more susceptible to oxidant injury accompanying reperfusion in rat pulmonary artery
ECs. We previously found that I/R-induced coronary endothelial dysfunction is mediated by
TNF. TNF expression in a model of partial coronary embolization can induce frank ischemia
and induce dysfunction [7,29,32]. Thus, this cytokine may have a key role in reperfusion injury.
Gurevitch et al. [13] have found in isolated, buffer-perfused rabbit hearts, anti-TNF improves
functional recovery following global ischemia. Our studies indicate therapies can and should
be tailored to remediate the in vivo level of TNF encountered in the pathology of endothelial
injury in myocardial I/R injury.
Previous studies [14,37,40] have shown that I/R produces impaired vascular endothelial
function as defined by abrogated endothelium-dependent dilation. This impairment has been
attributed to arginase [14], depletion of tetrahydrobiopterin [33], O2·−, cytokines, proteases
and lipid mediators [19]. Endothelium-derived NO is an important endogenous vasodilator that
regulates microvascular tone. The endothelial release of NO underlies the mechanism of
coronary arteriolar dilation to ACh [1,3]. The endothelial NO component was evident in the
present study because L-NMMA attenuated the ACh-induced vasodilation. Consistent with
our previous studies, we show here that ACh evokes dilation of coronary arterioles (probably
by activation of eNOS). In the present study, endothelium-dependent, ACh-induced
vasodilation in mouse coronary artery was impaired after I/R, whereas endothelium-
independent, SNP-induced vasodilation was normal, suggesting that I/R produces endothelial
dysfunction in a murine model of reperfusion injury. Endothelial function following I/R was
related to TNF expression. We studied the role of TNF by using different transgenic animals
expressing varying amounts of TNF. As follows, the dilation to ACh, or flow was the best in
the TNF−/−, worst in the TNF++/++ and intermediate in the WT and TNF−/++ mice. TNF++/++
mice survived well after I/R protocol, although TNF++/++ mice over-express large amounts of
TNF and exhibit more severe manifestations of I/R injury, e.g., contractile dysfunction. Our
results showed that the administration of neutralizing antibodies to TNF before the onset of
reperfusion lessened endothelial dysfunction in reperfusion injury in WT, TNF−/++ and
TNF++/++ mice, but did not affect responses in TNF−/− mice. In heterozygote TNF−/++ mice,
the plasma concentration of TNF in sham and after I/R injury was between TNF++/++ and WT
mice. In TNF−/− mice, the levels of TNF were below level of detection. The concentration of
TNF in the heart of TNF++/++ is very high [16]. We found that endothelial function is impaired
with a lower level of TNF in WT mice, and endothelial function is in between of these two
groups with a lower level of TNF in WT mice treated with anti-TNF. Our results suggest that
there is a dose dependency of TNF in endothelial dysfunction in I/R injury and I/R contributes
endothelial dysfunction via increasing TNF level in coronary arterioles. Importantly,
neutralizing antibodies to TNF restored FID to near the sham-control levels in I/R, as it did for
ACh. This is consistent with the likelihood that ROS limit the bioavailability of NO during I/
R injury, thus attenuating responses to the different endothelial-dependent stimuli. The
rationale for this dose of neutralizing antibody to TNF (1.6 mg/kg) was sufficient to neutralize
endogenous TNF based on previous studies [9,10,46]. We have also found this concentration
effectively neutralizes the actions of TNF.
Roles of O2·− in coronary vascular function in I/R injury
Endothelial dysfunction appears to occur early after reperfusion, signaled by the endothelial
generation of a large burst of superoxide radicals [8,11,20,28,29,31,36]. The decrease in
endothelium-dependent dilation has been shown to occur soon after the generation of O2·− by
the reperfused coronary endothelium [20,31] suggesting that endothelial generation of O2·−
radicals acts as a trigger mechanism for endothelial dysfunction. O2·− also reduces the
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bioavailability of NO, which would compromise dilation to endothelium-dependent stimuli.
Our results extend this knowledge by demonstrating that the administration of an O2·−
scavenger TEMPOL maintained vasodilation to ACh in I/R, but did not affect ACh-induced
vasodilation in sham groups in WT mice, and that TEMPOL partially restored ACh-induced
vasodilation following I/R injury in TNF−/++ and TNF++/++ mice, but did not affect that in
TNF−/− mice.
A recent study has shown that TNF inhibits NO-mediated endothelium-dependent
vasorelaxation in small coronary arteries via sphingomyelinase activation and consequent
O2·− production in ECs [47]. The source of O2·− and the signal transduction mechanism by
which TNF stimulation is linked to O2·− production was addressed using pharmacological
inhibitors of enzyme systems capable of producing O2·− during I/R previously [8,11,28,29,
31,42,45,46]. O2·− generation impairs NO-mediated coronary arteriolar function and we have
suggested that this oxidative free radical might be involved in TNF-induced vascular
dysfunction [44,46]. Although previous studies have shown that TNF increases the generation
of O2·− during I/R, it is unclear whether different levels of TNF induce different levels of
O2·− production in the vascular wall in microvessels after I/R. We studied the role of O2·− in
the WT, TNF−/− and transgenic TNF++/++ animals in I/R endothelial injury and evaluate its
production in animals under experimental conditions.
These studies established the link between TNF and ROS in the induction of endothelial injury
following myocardial I/R. Administration of an antibody to TNF at the time of reperfusion
prevented ROS generation [10], and mimics a clinically relevant paradigm in which an antibody
designed to neutralize TNF could be delivered at the time of a recanalization procedure or
restoration of flow following a coronary bypass. We also established the link between TNF
and the activation of O2·− generating enzymes using EPR spectroscopy to quantitatively
measure O2·− production from coronary arterioles during exposure to varying doses of TNF.
Our results indicated that O2·− production increased following I/R as compared to the sham
group, and importantly, administration of anti-TNF or TEMPOL reduced the expression of
O2·− to the level observed in the sham group. The finding of Pereda et al. [26] shows that
simultaneous inhibition of TNF production and xanthine oxidase activity greatly reduced local
systemic inflammatory response in acute pancreatitis. Our previous study [46] shows that I/R
injury increased the xanthine oxidase activity, and antibody to TNF and xanthine oxidase
inhibitor, allopurinol, separately attenuated the xanthine oxidase activity in I/R injury. Our
results demonstrate the production of TNF is essential in eliciting this oxidative stress.
In the present study, we show that O2·− production is enhanced in the TNF++/++ group before
and after I/R compared with WT groups; the production of O2·− is decreased in the TNF−/−
mice following I/R. The production of O2·− in TNF−/++ I/R mice is between TNF++/++ and
TNF−/− mice following I/R. This suggests there is a dose dependency of TNF in I/R-induced
O2·− production. This identifies a mechanism for and mechanisms by which TNF produces
endothelial dysfunction during I/R injury.
Roles of arginase in coronary vascular function in I/R injury
The overexpression of arginase by limiting the arginine pool would convert activated eNOS
(or any NOS) into an enzyme that produces O2·− instead of NO. Vasquez-Vivar et al. [38]
reported that eNOS can switch from an NO generating NAD(P)H oxidase to an O2·− generating
enzyme. We have found in previous studies [9,10,46] that TNF appears to be linked to
endothelial dysfunction and ROS generation in I/R injury. We also demonstrated that I/R
inhibits NO-mediated dilation of coronary arterioles by increasing arginase activity in ECs,
which limits the availability of L-arginine to NOS for NO production [14]. Arginase shares a
common substrate, L-arginine, with NOS. Molecular evidence in the porcine coronary arterioles
from our previous study indicated that arginase I, but not arginase II, mRNA and arginase I
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protein were expressed in the coronary arterioles [43]. Arginase II is the main isoform detected
in mitochondria [9,14,43], but we do not observe it in our preparation. Perhaps, it can be found
in mitochondria of other tissues because it is encoded by the nuclear genome and, therefore,
may show some tissue-specific expression. The arginase expressed in the endothelium plays
a counteracting role in the stimulated NO production, and thus in NO-mediated vasodilatory
function. It is possible that increased cytokines and/or reactive oxygen species mediate the
arginase activation. Both these factors are generated during myocardial I/R [17,18] and have
been shown to inhibit endothelium-dependent dilation in the coronary circulation [22]. Thus,
we postulated a link between TNF and arginase expression during I/R injury. We showed that
TNF expression is linked to arginase expression following cardiac I/R by demonstrating that
O2·− production was enhanced in the TNF++/++ group before and after I/R when compared with
WT groups. The production of O2·− is less in the TNF−/− mice following I/R versus the WT
mice following I/R. The production of O2·− was intermediate in TNF−/++ I/R mice when
compared with the TNF++/++ and TNF−/− mice following I/R. We previously showed that
antibody neutralization of TNF reduced arginase expression following I/R [9]. Our current
findings indicate that TNF increases arginase expression (mRNA and protein) in ECs and
represents one of the mechanisms by which TNF compromises endothelial function. The results
from NOS and arginase activity (Fig. 7) indicates that TNF increases the levels of O2·− due to
both increased arginase and decreased NOS activity scavenged NO and reduced its
bioavailability during I/R injury. Although we do not have a precise mechanism for the
alterations in NOS activity in the various lines, we speculate that the oxidative stress induced
by TNF overexpression can limit NOS activity by reducing levels of BH4, which is sensitive
to levels of ROS.
In conclusion, our results demonstrate that endothelial dysfunction occurring subsequent to I/
R injury is directly related to the level of TNF expression, which results in the production of
O2·− via increasing arginase expression. This suggests that there is a direct relationship between
levels of TNF expression and endothelial dysfunction in reperfusion injury. New animal
models, diagnostic techniques and therapeutic agents are expected to be developed from this
work. Knowledge gained from these studies provides a better understanding of the mechanism
(s) underlying endothelial dysfunction, defined as blunted endothelial dilation of coronary
arterioles, following myocardial I/R injury. The results of this study may contribute to the
development of novel adjunctive therapies using TNF antibodies or soluble receptors to prevent
microvascular endothelial dysfunction following I/R injury and/or during thrombolytic
therapies. The early appearance of TNF in the disease process and its association with
subsequent inflammation indicates that the role of TNF warrants further study. Understanding
endothelial dysfunction is critical because this condition precedes the development of coronary
disease; thus, if endothelial dysfunction can be rectified, the progression of vascular disease
may be halted [42]. Selective modulation of ROS signaling may provide a novel therapeutic
target to prevent or alleviate coronary diseases associated with TNF activation.
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Fig. 1.
The schematic figure shows that TNF expression compromises coronary endothelial function
by increasing arginase expression that results in ROS generation following myocardial I/R
injury
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Fig. 2.
ACh-induced vasodilation was not impaired in sham group when compared with the control,
but ACh-induced vasodilation was impaired after I/R in WT mice (Fig. 2a, n = 5). Anti-TNF
(n = 7) restored vasodilation to ACh in I/R versus sham. ACh-induced vasodilation was not
impaired in sham group and in I/R TNF−/− mice when compared with WT mice (Fig. 2b, n =
5). Anti-TNF (n = 7) did not affect the vasodilation to ACh in I/R and sham in TNF−/− mice.
In heterozygote TNF−/++ mice (Fig. 2c), ACh-induced endothelial-dependent vasodilation
following I/R was between TNF++/++ (Fig. 2d) and TNF−/− following I/R. Administering
neutralizing antibodies to TNF immediately prior to the onset of reperfusion-preserved
endothelial-dependent dilation following I/R in WT, TNF−/++ and TNF++/++ mice; n = number
of vessels; * P < 0.05 versus sham
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Fig. 3.
Isolated mice coronary arterioles from control mice (without I/R) dilated in a concentration-
dependent manner to flow (n = 6, Fig. 3). Flow-induced vasodilation was not impaired in sham
group when compared with the control, but flow-induced vasodilation was impaired after I/R
in WT mice (Fig. 3a, n = 5). In heterozygote TNF−/++ mice (Fig. 3c), flow-induced endothelial-
dependent vasodilation following I/R was between TNF++/++ (Fig. 3d) and TNF−/− (Fig. 3b)
following I/R. Neutralizing antibodies to TNF immediately prior to the onset of reperfusion-
preserved endothelial-dependent dilation following I/R in WT (Fig. 3a), TNF−/++ and
TNF++/++ mice. Figure 3e shows a dose–response curve for SNP in WT control mice before
and following I/R. There are no significant differences in endothelium-independent vasodilator
SNP-induced vasodilation (% of control diameter) before and after I/R. Figure 3f shows that
endothelial function is restored in I/R at WT mice treated with anti-TNF (mimicked the cross
of WT with the null animals), endothelial function is impaired with a lower level of TNF in
WT mice and endothelial function is in between of these two groups with a lower level of TNF
in WT mice treated with anti-TNF; n = number of vessels; * P < 0.05 versus sham
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Fig. 4.
Administration of a O2·− scavenger, TEMPOL (1 mmol/L, n = 7) restored vasodilation after I/
R. In WT, TNF−/++ and TNF++/++ mice, I/R-induced endothelial dysfunction was lessened
progressively by administration of free-radical scavenger TEMPOL immediately before
initiating reperfusion; n = number of vessels; * P < 0.05 versus sham
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Fig. 5.
EPR spectroscopy shows O2·− production increased in isolated coronary arteries in I/R mice
as compared to the sham (P < 0.05), and importantly, administration of anti-TNFα (Fig. 5a) or
TEMPOL (Fig. 5b) reduced the production of O2·− to the level observed in the sham in WT
mice. During I/R, production of superoxide (O−2) was greatest in TNF++/++ mice as compared
to WT, TNF−/++ and TNF−/− mice. * P < 0.05 versus sham; # P < 0.05 versus I/R
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Fig. 6.
The protein expression of arginase I was lower in TNF−/− mice, higher in TNF++/++ mice, and
in between of TNF−/− and TNF++/++ mice in TNF−/++ mice than that in WT mice (Fig. 6a, b).
Following I/R, arginase mRNA expression (Fig. 6c) was elevated in the WT, substantially
elevated in the TNF−/++ and TNF++/++ mice, and not affected in the TNF−/− mice. Antibody
neutralization of TNF decreased arginase expression in the WT, TNF−/++ and TNF++/++ mice,
but did not affect arginase expression in the TNF−/− mice. * P < 0.05 versus sham; # P < 0.05
versus I/R
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Fig. 7.
NOS activity (n = 7) and arginase activity (n = 6) were assayed in the coronary arteriolar lysate
to further elucidate the role of TNF in the upregulation of arginase in I/R (Fig. 7). We found
that reduced eNOS activity (Fig. 7a) in WT, TNF−/−, TNF−/++, TNF++/++ versus WT-sham
mice and arginase activity (Fig. 7b) is increased in I/R in WT-I/R, TNF−/++, TNF++/++ versus
WT-sham and TNF−/− mice
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Table 1
Levels of TNF (n = 9) at baseline (sham) and after I/R injury in WT, TNF−/++ and TNF++/++ mice
Groups Plasma concentration of TNF (pM/mI)
Sham (baseline) I/R
WT 1.2 ± 0.4 (9) 5.0 ± 0.6* (9)
TNF−/− Below level of detection Below level of detection
TNF−/++ 2.3 ± 0.3* (9) 6.9 ± 0.8*,# (9)
TNF++/++ 7.4 ± 1.2*,# (9) 13.6 ± 1.8*,# (9)
*
P < 0.05 versus WT-sham control and # P < 0.05 versus WT-I/R mice (n = 9)
In heterozygote TNF−/++ mice, the levels of TNF in sham and after I/R injury were in between of TNF++/++ and WT mice. In TNF−/− mice, the
levels of TNF were below the level of detection; n number of mice; * P < 0.05 versus sham
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